Alvin Shih, MD, MBA

Alvin is a physician executive and drug developer who is passionate about bringing together people, ideas, and resources to help patients and families affected by rare diseases. Alvin currently serves as CEO of Enzyvant Therapeutics, a development-stage biotechnology company focused on advancing transformative therapies for patients with rare diseases. Prior to joining Enzyvant, Alvin was the head of R&D at Retrophin, where he led the development of drugs for renal, metabolic, and neurological diseases. Earlier, Alvin helped establish the Pfizer Rare Disease Research Unit in Cambridge MA, and he started his career as a healthcare consultant for LEK Consulting and McKinsey & Company.

Alvin holds an MD from the University of Alabama, an MBA from the Kellogg School of Management at Northwestern University, and an undergraduate degree from Vanderbilt University. He completed his residency training in Internal Medicine at the Massachusetts General Hospital in Boston. He lives with his wife and three kids in the Boston area, and can be reached at Alvin.Shih@enzyvant.com.